September 26, 2007 / 12:32 PM / 10 years ago

Emergent BioSolutions signs $448 mln contract

Sept 26 (Reuters) - Emergent BioSolutions Inc (EBS.N) said it has signed a three-year contract worth $448 million with the U.S. health department, that includes delivery of anthrax vaccine, certain milestone payments and services.

The biopharmaceutical company said in a statement that it continues to expect full-year revenue growth of 10 percent to 15 percent, with a bias toward the upper end of the range, and positive net earnings. (Reporting by Deepti Chaudhary in Bangalore)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below